Literature DB >> 7698581

A single intraportal administration of follistatin accelerates liver regeneration in partially hepatectomized rats.

K Kogure1, W Omata, M Kanzaki, Y Q Zhang, H Yasuda, T Mine, I Kojima.   

Abstract

BACKGROUND/AIMS: Activin A is an autocrine negative regulator of DNA synthesis in rat hepatocytes and is expressed in remnant liver after partial hepatectomy. To determine the role of activin A in liver regeneration, the effects of exogenous follistatin, which blocks the action of activin A, were examined.
METHODS: Human recombinant follistatin was infused into the portal vein immediately after 70% hepatectomy. Changes in body weight, remnant liver weight, liver regeneration rate, and nuclear bromodeoxyuridine labeling were measured.
RESULTS: In control rats, nuclear labeling was observed at 24 hours and peaked at 36 hours after the hepatectomy. In follistatin-treated rats, nuclear labeling was first observed after 18 hours and was significantly (P < 0.05) greater than that in control rats at 24 hours. In follistatin-treated rats, both remnant liver weight and liver regeneration rate were significantly greater at 120 hours. Serum concentrations of albumin and glucose remained reduced for up to 120 hours in control rats but recovered in follistatin-treated rats.
CONCLUSIONS: A single administration of follistatin accelerates the initial round of DNA synthesis after partial hepatectomy. Activin A produced in remnant liver may exert tonic inhibitory effect on liver regeneration. Follistatin may be useful as a potential therapeutic agent to promote liver regeneration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7698581     DOI: 10.1016/0016-5085(95)90212-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

1.  Endothelial transcription factor KLF2 negatively regulates liver regeneration via induction of activin A.

Authors:  Yosif Manavski; Tobias Abel; Junhao Hu; Dina Kleinlützum; Christian J Buchholz; Christina Belz; Hellmut G Augustin; Reinier A Boon; Stefanie Dimmeler
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-27       Impact factor: 11.205

2.  Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression.

Authors:  N A Shackel; P H McGuinness; C A Abbott; M D Gorrell; G W McCaughan
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

3.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

4.  Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration.

Authors:  A L Lau; T R Kumar; K Nishimori; J Bonadio; M M Matzuk
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 5.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

6.  Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis.

Authors:  N Ohnishi; T Miyata; H Ohnishi; H Yasuda; K Tamada; N Ueda; H Mashima; K Sugano
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Tob1 is a constitutively expressed repressor of liver regeneration.

Authors:  Karen J Ho; Nhue L Do; Hasan H Otu; Martin J Dib; Xianghui Ren; Keiichi Enjyoji; Simon C Robson; Ernest F Terwilliger; Seth J Karp
Journal:  J Exp Med       Date:  2010-05-31       Impact factor: 14.307

Review 8.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomy.

Authors:  F Xue; T Takahara; Y Yata; Y Kuwabara; E Shinno; K Nonome; M Minemura; S Takahara; X Li; E Yamato; A Watanabe
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 10.  Preoperative portal vein embolization for hepatocellular carcinoma: Consensus and controversy.

Authors:  Taku Aoki; Keiichi Kubota
Journal:  World J Hepatol       Date:  2016-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.